The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
Open accessAbstract
Incubation of resting lymphoid cells with recombinant interleukin 2 (IL-2) in vitro leads to the generation of lymphokine activated killer (LAK) cells capable of lysing fresh tumor cell suspensions in short-term chromium-release assays. Our previous studies (7) have demonstrated that the injection of LAK cells plus low doses of recombinant IL-2 were capable of inhibiting the growth of pulmonary metastases. We have now explored the ability of high doses of recombinant IL-2, administered systemically, to generate LAK cells in vivo, and to mediate antitumor effects directly. Administration of increasing doses of recombinant IL-2 intraperitoneally resulted in the generation of LAK cells in the spleens of recipient mice. Doses of 100,000 U recombinant IL-2 administered intraperitoneally approximately every 8 h for 5 d were capable of dramatically inhibiting established 3-d pulmonary metastases from the MCA-105 and MCA-106 syngeneic sarcomas and the syngeneic B16 melanoma in C57BL/6 mice. Grossly visible metastases present at 10 d after tumor injection also underwent regression following IL-2 therapy. Surprisingly, established 10 d pulmonary metastases were more susceptible to the effects of IL-2 than were the smaller 3 d pulmonary metastases. All antitumor effects of the systemic administration of recombinant IL-2 were eliminated if mice received prior treatment with 500 rad total body irradiation. The administration of high doses of recombinant IL-2 was also capable of inhibiting the growth of 3-d established subcutaneous tumors from the MCA-105 sarcoma, and of mediating the inhibition of growth and regression of established palpable subcutaneous MCA-105 sarcomas. Lymphocytes, which appeared morphologically to be activated, were present at the site of regressing tumor, and it appears that the mechanism of the antitumor effect of recombinant IL-2 administered systemically is via the generation of LAK cells in vivo, although this hypothesis remains to be proven. The ready availability of high doses of recombinant human IL-2, and the demonstration of antitumor effects seen in animal models have led us to the initiation of the clinical trials of recombinant IL-2 in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,406
Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
Morgan, D. A., Ruscetti, F. W., & Gallo, R. (1976) · Science · doi:10.1126/science.181845 · Cited by 2,493
Grimm, E. A., Mazumder, A., Zhang, H. Z., & Rosenberg, S. A. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.6.1823 · Cited by 2,204
Self-citationT cell growth factor receptors. Quantitation, specificity, and biological relevance
Robb, R., Munck, A., & Smith, K. (1981) · The Journal of Experimental Medicine · doi:10.1084/jem.154.5.1455 · Cited by 1,061
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Self-citationBiological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., & Mark, D. F. (1984) · Science · doi:10.1126/science.6367046 · Cited by 595
Self-citationLysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.
Lotze, M. T., Grimm, E. A., Mazumder, A., Strausser, J. L., & Rosenberg, S. A. (1981) · PubMed · Cited by 523
Self-citationGrimm, E., Ramsey, K., Mazumder, A., Wilson, D., Djeu, J., & Rosenberg, S. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.157.3.884 · Cited by 467
Self-citationAccurate Identification of Experimental Pulmonary Metastases2
Wexler, H. (1966) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/36.4.641 · Cited by 407
The fate of interleukin-2 after in vivo administration.
Donohue, J. H., & Rosenberg, S. A. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.5.2203 · Cited by 375
Self-citationMazumder, A., & Rosenberg, S. A. (1984) · The Journal of experimental medicine · doi:10.1084/jem.159.2.495 · Cited by 369
Self-citationRosenstein, M., Yron, I., Kaufmann, Y., & Rosenberg, S. A. (1984) · PubMed · Cited by 297
Self-citationCheever, M. A., Greenberg, P. D., Fefer, A., & Gillis, S. (1982) · The Journal of experimental medicine · doi:10.1084/jem.155.4.968 · Cited by 265
Yron, I., Wood, T. A., Spiess, P. J., & Rosenberg, S. A. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.1.238 · Cited by 264
Self-citationDonohue, J. H., Rosenstein, M., Chang, A. E., Lotze, M. T., Robb, R. J., & Rosenberg, S. A. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.4.2123 · Cited by 143
Self-citationLysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.
Mazumder, A., Grimm, E. A., Zhang, H. Z., & Rosenberg, S. A. (1982) · PubMed · Cited by 99
Self-citationSystemic administration of recombinant human interleukin-2 in mice.
Chang, A. E., Hyatt, C. L., & Rosenberg, S. A. (1984) · PubMed · Cited by 85
Self-citation
Cited by
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Self-citationRosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., Ettinghausen, S. E., Matory, Y. L., Skibber, J. M., Shiloni, E., Vetto, J. T., et al. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132327 · Cited by 2,653
Self-citationAdoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Self-citationRosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389
Self-citation
Metadata
- Authors
- Rosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1985-05-01
- Volume
- 161
- Issue
- 5
- Pages
- 1169-1188
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2130537353
- Cited by
- 745
- References
- 17
- FWCI
- 18.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.